Pyrimidinone amide compounds as PDE2 inhibitors

Patent metadata

Field	Value
Publication number	US-10285989-B2
Application number	US-201615573858-A
Country	US
Kind code	B2
Filing date	May 10, 2016
Priority date	May 15, 2015
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.

First claim

What is claimed is:

1. A compound represented by structural formula I:

or a pharmaceutically
acceptable salt thereof,
wherein:
R 1 is linked to the pyrimidinone via an atom other than carbon and is selected from the group consisting of halo, —OR, O(CH 2 ) 1-3 OR, O(CH 2 ) 1-3 N(R) 2 , O(CH 2 ) n C(R) 2 OR, O-(CH 2 ) n C 4-10 heterocyclyl, O-(CH 2 ) 1-3 OC 6-10 aryl, O—C 6-10 aryl, N(R x ) 2 , —NRC 5-10 heterocyclyl, —NRC 6-10 aryl, —NRC 3-10 cycloalkyl, SR, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with one to three groups of R a ;
R 1a represents H, or C 1-6 alkyl, said alkyl optionally substituted with OH or halo,
R 2 and R 3 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, (CH 2 ) n CN, C(O)R, C(O)OR, CF 3 , —C 3-10 cycloalkyl, C 6-10 aryl, C 5-10 heteroaryl, said alkyl, cycloalkyl, aryl and heteroaryl optionally substituted with one to three groups of R b ;
R 2 and R 3 can combine with the carbon atom to which they are attached to form a C 3-6 cycloalkyl, said cycloalkyl optionally interrupted with 1-2 heteroatoms selected from O, S, or N and optionally substituted with one to three groups of R b
R 4 represents hydrogen, halo, or C 1-6 alkyl; or alternatively,
R 2 and R 3 along with the carbon atom to which they are attached and the R 4 on the phenyl ring can combine to form a C6-10 bicyclic ring which includes the phenyl ring, said bicyclic ring optionally interrupted with 1-2 heteroatoms selected from O, S, and N and optionally substituted with one to three groups of R b ;
R represents H, or C 1-6 alkyl;
R a is selected from the group consisting of H, halo, CN, C 1-6 alkyl, (CH 2 ) n OR, (O) p C 1-4 haloalkyl, S(O) s CF 3 , S(O) s R, SF 5 , C 3-10 cycloalkyl, said alkyl and cycloalkyl optionally substituted with one to three groups of R b ;
R b is selected from the group consisting of H, halo, C 1-6 alkyl, SO 2 C 1-6 alkyl, and (O) p C 1-4 haloalkyl;
each occurring R x independently represents H, or C 1-6 alkyl, or two adjacent R x groups can combined together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl optionally substituted with one to three groups of R b ;
n represents 0, 1, 2, 3, or 4;
s represents 0, 1, or 2; and
p represents 0 or 1.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 1a is hydrogen.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of OR, O(CH 2 ) 1-3 OR, O(CH 2 ) n C(R) 2 OR, and O(CH 2 ) 1-3 N(R) 2 and optionally substituted O—(CH 2 ) n C 4-10 heterocyclyl said heterocyclyl is selected from the group consisting of oxetanyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimindyl, tetrahydropyranyl, pyrazolyl, and azetidinyl.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group N(R x ) 2 , —NRC 5-10 heterocyclyl, —NRC 6-10 aryl, and NRC 3-10 cycloalkyl, said cycloalkyl, aryl and heterocyclyl optionally substituted with one to three groups of R a .

5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof wherein R 1 is N(R x ) 2 and the two adjacent R x groups are combined together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl selected from the group consisting of optionally substituted pyrrolidinyl, pyrazolyl, azetidinyl, piperidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimidinyl, and dihydropyrrolopyridinyl.

6. The compound according to claim 3 or a pharmaceutically acceptable salt thereof wherein R 1 is O-(CH 2 ) n C 4-10 heterocyclyl, said heterocyclyl optionally substituted with one to three groups of R a .

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from the group consisting of SCH 3 , —N(CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), N(CH 2 CH 3 ) 2 , —NH 2 , —NHCH 3 , NH-cyclobutyl, NH-cyclopentyl, NH-cyclopropyl, NH-pyridyl, —OR, —O-phenyl, —O(CH 2 ) 2 OCH 3 , —O(CH 2 ) 3 OCH 3 , —O(CH 2 ) 3 OCH(CH 3 ) 2 , —O(CH 2 ) 2 N(CH 3 ) 2 , —O(CH 2 ) 2 C(CH 3 ) 2 OCH 3 , —OCH 2 oxetanyl, —O(CH 2 ) 4 OCH 3 , —O(CH 2 ) 3 NHCH 3 , —O-tetrahydrofuranyl, —O-piperidinyl, —O-oxetanyl, —O(CH 2 ) 3 Ophenyl, O(CH 2 ) 2 CH(CH 3 )OCH 3 , —O-tetrahydropyranyl, O-pyrrolidinyl, N linked pyrazolyl, N linked azetidinyl, N linked pyrrolidinyl, and N linked piperidinyl, said cyclobutyl, cyclopentyl, cyclopropyl, phenyl, oxetanyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, pyrollidinyl, pyrazolyl, and azetidinyl optionally substituted with one to three groups of R a .

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from N(CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), N(CH 2 CH 3 ) 2 , —NH 2 , —NHCH 3 , and optionally substitiuted NH-cyclobutyl, NH-cyclopentyl, NH-cyclopropyl, and NH-pyridyl.

9. The compound according to claim 8 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from N(CH 3 ) 2 .

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein one of R 2 and R 3 is hydrogen or CH 3 and the other is C 1-6 alkyl or C 3-10 cycloalkyl, said alkyl and cycloalkyl optionally substituted with one to three groups of R b .

11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof wherein the C 1-6 alkyl is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and the optionally substituted C 3-10 cycloalkyl is selected from cyclopropyl, cyclobutyl, and cyclopentyl.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof wherein the C 1-6 alkyl is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , and CH 2 CH 3 , and the optionally substituted C 3-10 cycloalkyl is cyclopropyl.

13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 2 and R 3 combine with the carbon atom to which they are attached to form a C 3-10 cycloalkyl, said cycloalkyl optionally substituted with one to three groups of R b .

14. The compound according to claim 13 wherein the C 3-10 cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl.

15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R a is selected from OH, halo, CH 3 , optionally substituted cyclopropyl, (CH 2 ) n OCH 3 , CH 2 F, (CH 2 ) n CF 3 , OCHF 2 , OCF 3 , SCH 3 , SCF 3 , SF 5 , SOCF 3 , SO 2 CF 3 , SO 2 CH 3 , CH 2 NH 2 , and (CH 2 ) n N(CH 3 ) 2 .

16. The compound according claim 1 or a pharmaceutically acceptable salt thereof represented by structural formula II:

wherein R 1 is selected from the group consisting of —N(CH 3 ) 2 , NH 2 , NHCH 3 , O(CH 2 ) 3 NHCH 3 , and optionally substituted O-tetrahydrofuranyl, N linked pyrazolyl, N linked pyrrolidinyl, O-pyrrolidinyl, or O-piperidinyl, R 3 is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and optionally substituted cyclopropyl, and R a is selected from the group consisting of SCF 3 , CF 3 , OCF 2 , O

Assignees

• Merck Sharp & Dohme

Inventors

• Shen Dong-Ming
• Wang Deping
• Qian Xiaoxia
• Harper Bart
• Yang Meng
• Bo Yingjian

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/22

  Anxiolytics · CPC title

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title

• C07D405/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D239/52

  Two oxygen atoms · CPC title